Entries by

The use of Genomic Allergen Rapid Detection (GARD) assays to predict the respiratory and skin sensitising potential of e-liquids

Regulatory Toxicology and Pharmacology. Volume 103, April 2019, Pages 158-165 https://doi.org/10.1016/j.yrtph.2019.01.001 Matthew Stevenson, Lukasz Czekala, Liam Simms, Nicole Tschierske, Olivia Larne, Tanvir Walele Abstract Electronic cigarettes (e-cigarettes) are an increasingly popular alternative to combustible tobacco cigarettes among smokers worldwide. A growing body of research indicates that flavours play a critical role in attracting and retaining […]

SenzaGens attended BioFIT in Lille, France

On December 4-5, SenzaGen was attending BioFIT in Lille, France. BioFIT is a business development meeting with focus on early stage innovations including pre-clinical stage assets. We met with CROs and life science companies from all over Europe in search of screening tools at pre-clinical stage. Read more about Biofit here: https://www.biofit-event.com

SenzaGen attends Society of Toxicology (STC) of Canada’s 50th Annual Symposium

SenzaGen is attending the Society of Toxicology (STC) of Canada’s 50th Annual Symposium, on December 10-12 in Toronto, Canada. Joshua Schmidt, Business Development Director Americas at SenzaGen, will participate at the symposium and present the poster:  GARD – Assessing Skin and Respiratory Sensitizers in vitro using a genomics-based platform. STC is a non-profit association whose objectives […]

SenzaGen speaks at Eurofins Human Safety Seminar, November 29

Dr Andy Forreryd, scientist at SenzaGen, is one of three speakers at the Human Safety Seminar organised by Eurofins BioPharma Product Testing Munich where he will be presenting the GARD® platform for skin and respiratory sensitization. The seminar will be hosted on November 29 at the new laboratory and office building of Eurofins Munich, Robert-Koch-Straße 3a in Planegg near Munich, Germany. […]

SenzaGen attends the Biocompatibility Summit in Barcelona

SenzaGen is attending the Biocompatibility Summit in Barcelona this week, on November 27-29. The summit will address updates and changes to the ISO 10993 standards and Biocompatibility for devices with a focus on Risk Mitigation, Chemical Characterisation and Practical Implementation. Come meet our colleagues and specialists Rose Marie Jenvert, Medical Device Project Manager and Joshua Schmidt, […]

SenzaGen attends the SFT annual meeting, November 27-28

SenzaGen is attending the SFT conference (Société Française de Toxicologie) in Lille, France, on November 27-28. The conference is the French Society of Toxicology’s annual meeting and SenzaGen is present with a poster: GARD® – Genomic Allergen Rapid Detection, In vitro Safety Assessment of Skin and Respiratory Sensitizers using a Genomics Based Platform. Our French […]

SenzaGen’s presentation at Unicorn Summit

On October 10, SenzaGen participated in the Vator Securities Unicorn Summit, a capital market day organized to bring together some of the most innovative and fast-growing Swedish life science companies with investors. Anki Malmborg Hager presented Senzagen’s developments and accelerated efforts towards further strengthening the commercial organization and the global presence of GARD®, a group of tests for animal-free safety testing. […]

Anki Malmborg Hager interviewed by EFN (in Swedish)

On October 15, SenzaGen’s CEO Anki Malmborg Hager was interviewed by Swedish financial media EFN about SenzaGen’s cruelty-free test platform GARD®, our business model and new sales targets. The result was a short and to-the-point interview about our core business and our future. You will find the filmed interview (in Swedish) here: https://www.efn.se/bors-finans/senzagen-ersatter-djurforsok-kemikalietester/

A mechanistic reinterpretation of the AOP for skin sensitisation

David W Roberts, Liverpool John Moores University, Liverpool Introduction – Non-Animal Prediction: the 21st Century Consensus Because of the biological complexity of the skin sensitisation process no single in chemico or in vitro assay will be an appropriate replacement for an animal-based assay such as LLNA or GPMT… …to ensure a mechanistic basis and cover the […]